Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
Wednesday, December 20, 2023BioMed X announced today a new joint research project with Ono Pharmaceutical Co Ltd marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
Wednesday, December 20, 2023MAIA Biotechnology Inc a clinicalstage biopharmaceutical company developing telomeretargeting immunotherapies for cancer today announced dose selection for THIO
European Commission Approves KEYTRUDA® Plus Chemotherapy for New Indications in Advanced Gastric Cancer and Biliary Tract Cancer
Tuesday, December 19, 2023Merck known as MSD outside of the United States and Canada today announced the European Commission EC has approved two new indications for KEYTRUDA
Lexeo Therapeutics Receives FDA Fast Track and Orphan Drug Designations for LX2020 in PKP2 ACM
Tuesday, December 19, 2023Lexeo Therapeutics Inc a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOEassociated Alzheimers disease
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy
Monday, December 18, 2023Santhera Pharmaceuticals announces that AGAMREE has been approved in the European Union for the treatment of Duchenne muscular dystrophy DMD in patients years of age and older
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
Saturday, December 16, 2023Biogen Inc announced the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for SKYCLARYS for the treatment of Friedreichs ataxia
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
Friday, December 15, 2023Cullinan Oncology Inc a biopharmaceutical company focused on modalityagnostic targeted oncology therapies today announced that the first patient has been dosed with CLN in a Phase clinical trial
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
Friday, December 15, 2023ITM Isotope Technologies Munich SE a leading radiopharmaceutical biotech company today announced that it has executed its license agreement with Merck a leading science and technology company
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
Friday, December 15, 2023BioPath Holdings Inc a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
Thursday, December 14, 2023Editas Medicine Inc a clinicalstage genome editing company today announced that the Company and Vertex Pharmaceuticals entered into a license agreement Under terms of the agreement Vertex will obtain
